Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective ; volume:20 ; number:1 ; day:10 ; month:11 ; year:2020 ; pages:1-14 ; date:12.2020
BMC cancer ; 20, Heft 1 (10.11.2020), 1-14, 12.2020

Creator
Sureda, Anna
André, Marc
Borchmann, Peter
Silva, Maria G. da
Gisselbrecht, Christian
Vassilakopoulos, Theodoros P.
Zinzani, Pier Luigi
Walewski, Jan
Contributor
SpringerLink (Online service)

DOI
10.1186/s12885-020-07561-2
URN
urn:nbn:de:101:1-2020122123264959695180
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Sureda, Anna
  • André, Marc
  • Borchmann, Peter
  • Silva, Maria G. da
  • Gisselbrecht, Christian
  • Vassilakopoulos, Theodoros P.
  • Zinzani, Pier Luigi
  • Walewski, Jan
  • SpringerLink (Online service)

Other Objects (12)

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Related objects